What all this cancer news means for medicine at large
MedCity News | June 09, 2017
If you’re not in the field of oncology, you might be getting sick of all the cancer buzz dominating healthcare news feeds over the last few weeks. There was the historic FDA approval of Merck’s Keytruda, an immunotherapy, for a genetic biomarker rather than a tissue of origin. It is now indicated for a range of solid tumors (breast, colon, pancreatic etc.), as long as the mutated cells carry so-called mismatched repair genes.